Novavax Coronavirus Vaccine is Safe, Effective: Study
Early-stage clinical trials have shown that the Coronavirus vaccine developed by US-based biotechnology company Novavax, is safe and effective.
The company in early August announced the results, according to a study published in The New England Journal of Medicine on Wednesday.
The study shows 131 healthy adult people have tested for the vaccine in early May. Of these, adjuvants with vaccines were applied to the bodies of 83 people, CNN reports. Adjuvant helps to increase immunity. In addition, 25 people have taken the vaccines without adjuvants. And 23 other people got placebo. Placebo is an ineffective replica during a drug or vaccine test.
The volunteers were all residents of two Australian regions and all were under the age of 60. The participants have no record of infection with Covid-19. Also, they have not recovered from the infection.
The participants have received a second injection 21 days after the first. Also, the researchers looked at whether the vaccine was safe in the first tests at an early stage. They kept it under observation whether the vaccine is causing any reaction.
Thirty-five days later, nothing harmful or unusual happened in anyone’s body, the study added. However, after administering the vaccine for a second time, one person developed a slight fever that lasted for one day. Apart from this, nothing harmful happened in most of the cases.
Besides, the researchers found no adverse events occurred in the most individuals after the second trial. Only eight have joint pain and fatigue.
The body produced neutralizing antibodies after the second time of the trial. Neutralizing antibodies may inactivate the efficacy of Coronavirus.
The antibodies are four to six times more than the antibodies made in the body of those volunteers who have recovered from the disease.
On the other hand, the vaccine seemed to make T-cells in the body. T-cells are a type of white blood cell that helps the immune system detect and prevent infected cells.
According to the study, the benefits of using the adjuvant with the vaccine are clear, CNN reports.
To Read Our Exclusive Content, Sign up Now.
$5/Monthly, $50/Yearly
